Summary.-Sera from breast cancer patients and from female controls were tested for inhibition of lysis of antibody-coated target cells by human leucocytes (K cells). Sera from 39 ,' of breast cancer patients, but from only 8°of controls, inhibited lysis by more than 30%O. This inhibition was unrelated to the stage of the disease, the patient's age or whether the patient was pre-or post-operative. Inhibition was apparently not due to anti-HLA antibodies and did not correlate with the IgG level or anti-complementary activity of the serum. On fractionation by gel-filtration, inhibitory activity was found in fractions of higher molecular weight than IgG.
MANY cancer patients have impaired immunological competence, especially later in the course of their disease. The basis of this impairment remains largely unknown, although sera from patients with widely different cancers can depress T lymphocyte function in vitro as measured by PHA stimulation (Silk, 1967; Whittaker, Rees and Clark, 1971; Gatti, 1971) . Sera from breast cancer patients can also reduce E rosette formation, another T lymphocyte property (Whitehead et al., 1976) . However, the effect of cancer serum on the function of other types of lymphoid cell appears to have been relatively unexplored. In this study, sera from breast cancer patients have been tested for inhibition of K cell function. K cells are non-phagocytic lymphoid cells responsible for killing antibody-coated target cells (Perlmann and Holm, 1968; MacLennan and Loewi, 1968) . This mechanism is potentially of importance in tumour rejection (Hersey, 1973) .
MATERIALS AND METHODS
Patients.-Patients ranged in age between 37 and 83 years (mean ± s.d., 59-8 + 12-2) and were attending an outpatients breast cancer clinic. None of these women had received chemo-or radiotherapy in the previous 12 months. All patients were staged using clinicopathological data according to the TNM classification; Stage 1, T1_2NoMo; Stage 2, T1_2N1M0; Stage 3, T3 4N o-2Mo; Stage 4, T1 4N0 3M1 where T, N and M represent respectively tumour size, the number of lymph nodes involved, and whether or not there is metastasis. The mean ages of the patients in the 4 stages were: Stage 1, 60-2 i 13-9; Stage 2, 60-1 + 12-6: Stage 3, 59-7 11-5; Stage 4, 57-9 ± 12-0.
Controls-.Controls were healthy women, mostly laboratory or office staff aged between 41 and 72 years (mean 53-3 + 7-9).
Sera.-Blood was obtained by venepuncture, allowed to clot at room temperature for 30 min and kept at 4°C for 2 h before collection of the serum by centrifugation. Sera were either stored at 4°C and used within 1 week of collection, or stored at -20°C until required. To avoid aggregation of IgG, sera were not heat-activated, but left overnight at room temperature before assay to remove the bulk of the complement activity.
Inhibition of K cell killing.-Sera were tested for their capacity to inhibit lysis of antibody-coated Chang target cells by K cells (MacLennan and Loewi, 1968) . Normal human leucocytes from laboratory personnel were used as the source of K cells.
Peripheral blood leucocytes were obtained from heparinized blood by Hypaque/Ficoll centrifugation and washed x 3. Although the leucocyte suspension contained up to 15% monocytes and polymorphs, these cells did not lyse antibody-coated Chang cellsas shown by separate experiments using plastic adherence to remove the phagocytic cells.
Chang liver cells (106) were labelled with 51Cr (Brunner et al., 1968) , incubated for 30 min at 37°C with 1 ml of a 1/500 dilution of rabbit anti-human fibroblast serum, and washed twice. This is a sub-complementfixing amount of antiserum. The antiserum was raised by giving 3 weekly injections of 106 cells and bleeding 1 week after the last injection.
Sera (25 ,ul) were dispensed into the wells of Microtest II plates (Falcon Plastics) and 75 ,ul of a human leucocyte suspension (1.5 x 105 cells) was added, followed by 100 ,ul of a suspension of 51Cr-labelled, antibody-coated Chang cells (104). After 17 h incubation at 37°C in 5 % C02: 95 % air, 100 ,lI of supernatant was removed for y counting. Each test was set up in quadruplicate, using Eagle's minimum essential medium containing 10% foetal calf serum as diluent. Inhibition of cytotoxicity was calculated from the formula 100 (a-b)/(a-c) where a, b and c are the mean ct/min 51Cr released from antibodycoated Chang cells by respectively, leucocytes + medium, leucocvtes + test serum, and medium alone. The %51Cr released by medium alone or by leucocytes + medium ranged from 17% to 35% and from 80% to 95% respectively (10 experiments). The standard deviation of quadruplicate cultures was always less than 7 % of the mean, and usually less than 5%. For all of the lymphocyte donors used, " spontaneous " killing of non-antibody-coated Chang cells was less than 10%, and hence this effect was not taken into account when calculating inhibition of lysis of antibody-coated Chang cells. In each test, sera from controls and from cancer patients were included, and the data from all tests were plotted in Fig. 1 .
Rheumatoid factor estimation.-The RoseWaaler method was employed. Sera were tested for agglutination of rabbit IgGcoated sheep erythrocytes.
Erythrocytes (1%, v/v) were incubated for 30 min at room temperature with an equal volume of rabbit anti-sheep erythrocyte serum (Wellcome Reagents), diluted 10 times beyond its haemagglutination titre. Equal volumes of the coated cells and test serum dilutions were incubated overnight at 4°C in round-bottomed microplates (Cooke Engineering) . Results were expressed as the minimum serum dilution which agglutinated at least half of the cells. Before testing, all sera were absorbed with sheep erythrocytes.
HLA typing.-Sera were tested by the NIH lymphocytotoxicity technique (Brand et al., 1970) against selected lymphocytes, covering the following HLA antigens: HLA-A 1, 2, 3, 9, 11, 28, 29, w30, w31, w32. HLA-B 5, 7, 8, 12, 14, 18, 27, w15, w16, w17, w21, w22, w35, w40 . Typing was kindly performed by Mr C. Darke at the Welsh Regional Transfusion Centre, St Fagans.
Estimation of IgG levels.-The radial immunodiffusion method was used (Mancini, Carbonara and Heremans, 1965) .
Serum fractionation by gel-filtration.-Sera (1 ml) were fractionated at room temperature on a (1-5 x 90) cm column of Ultrogel AcA34, equilibrated with sterile Dulbecco's phosphate-buffered saline, pH 7.5. A flow rate of 3 ml/h was used and 2-ml fractions were collected at 4°C. Appropriate fractions were pooled and sterilized using a 0-2-,um filter.
Inhibition of complement (C') fixation. Sera were tested for inhibition of C'-dependent lysis of antibody-coated sheep erythrocytes.
Thrice-washed erythrocytes (1 ml packed cells) were incubated for 45 min at 37°C with 50 ml of a 1/500 dilution of rabbit haemolysin (Wellcome Reagents) in C' fixation buffer (Oxoid), washed once and resuspended at 2% (v/v) Secondly, the presence of anti-HLA antibodies in sera could cause inhibition at the K cell level. Anti-HLA antibodies can be detected in multiparous women and in patients after blood transfusion. It was considered that the first variable could be allowed for by using age-matched female controls. However, as many of the breast cancer patients were tested post-operatively (i.e. post-transfusion), it was important to compare the inhibitory activity of sera from pre-operative and post-operative patients. From Fig. 2 it can be seen that sera of pre-operative patients were at least as inhibitory as postoperative sera. There are 2 further lines of evidence against a role for anti-HLA antibodies: (a) none of 6 "inhibitory" sera tested against a pool of typed lymphocyte donors had detectable anti-HLA activity; (b) in one experiment, 20 breast cancer sera were tested against Kcells from 2 donors of different HLA type, and found to have a similar order of inhibitory activityconsistent with the data in Table I. K cell function can be inhibited by aggregated IgG or by immune complexes containing IgG antibody (MacLennan, 1972 might be expected to be related to the serum concentration of IgG, there was no direct correlation between IgG concentration and the K cell inhibitory activity of breast cancer sera (correlation coefficient -0.46). Gel-filtration using Ultrogel AcA34 was used for the partial characterization of the inhibitory factor. The IgG-rich fraction of all sera tested (either " inhibitory " or " non-inhibitory ") became inhibitory after gel-filtration, presumably because of partial denaturation during the separation procedure. However, 3 of 4 " inhibitory " sera had additional activity in fractions of higher molecular weight than IgG, although no IgG could be detected in these fractions by radial immunodiffusion.
Inhibition of C' fixation
As immune complexes can have anticomplementary activity, it was of interest to compare normal and breast cancer sera for inhibition of C' fixation (Table II) . Only Stage 4 sera showed increased anticomplementary activity compared to normal sera (P 0.02). There was no correlation between the anti-complementary activity of individual sera and their capacity to inhibit K cell cytotoxicity.
DISCUSSION
Approximately 3900 of breast cancer sera, but less than 80% of normal sera, inhibited K cell cytotoxicity by more than 3000. The effect was present at all stages of the disease, in both pre-operative and post-operative patients, and was ageindependent. Inhibition was not due to rheumatoid factor and apparently not to anti-HLA antibodies and did not correlate with serum IgG levels or anti-complementary activity.
Characterization of the K cell inhibitory factor by gel-filtration on an Ultrogel column revealed that the IgG fraction of both " inhibitory " and " noninhibitory" sera acquired inhibitory activity. A similar effect has been noted using ion-exchange chromatography (MacLennan and Howard, 1972) . Despite this, additional inhibitory activity was found in fractions of higher molecular weight than monomeric IgG. As these fractions contained no IgG detectable by radial immunodiffusion, we cannot at this stage conclude that the inhibitory factor is an IgG-containing immune complex.
Anti-complementary activity of breast cancer sera had a much lower incidence than K cell inhibition, and the 2 effects did not correlate. As anti-complementary activity is usually mediated by large immune complexes (Weigle, 1961) , it is unlikely that this type of complex is responsible for K cell inhibition by breast cancer sera.
There have been previous reports of serum inhibition of K cell killing. Jewell and MacLennan (1973) found inhibitory immune complexes in the sera of patients with inflammatory bowel disease, while Matthews et al. (1976) reported that sera from rats bearing a squamous cell carcinoma inhibited K cell activity. In this latter report, the effect was also independent of the stage of tumour growth.
As inhibition was noted with control sera, albeit to a lesser extent, the inhibitory factor may be a normal component of serum which is elevated in some breast cancer sera. Proof of this requires further characterization of the K cell inhibitory factor, and this is currently being attempted. Whatever the nature of the factor it may well contribute to the immunosuppression in a proportion of breast cancer patients.
